Tranexamic acid is a synthetic derivative of the amino acid lysine.Tranexamic acid (commonly marketed in tablet form as Lysteda and in IV form as Cyklokapron in the U.S. and as Transamin, Transcam in Asia, and Espercil in South America) is often prescribed for excessive bleeding.Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin, a molecule responsible for the degradation of fibrin. Fibrin is the basic framework
for the formation of a blood clot in hemostasis.Tranexamic acid has roughly 8 times the antifibrinolytic activity of an older analogue, ε-aminocaproic acid
Tranexamic acid exerts its antifibrinolytic effect through the reversible blockade of lysine-binding sites on plasminogen molecules.Tranexamic acid inhibits endometrial plasminogen activator and thus prevents fibrinolysis and the breakdown of blood clots.
Tranexamic acid is used as firstline nonhormonal treatment of dysfunctional uterine bleeding, and heavy bleeding associated with uterine fibroids. The histological appearance of the necrosis in women treated by tranexamic acid is no different from the spontaneous incidence of thrombosis.
Tranexamic acid is used in orthopedic surgery to reduce bloodloss. Tranexamic acid is of proven value in clearing the field of surgery and reducing pre- and postoperative blood loss. Drain and number of transfusions are reduced. Tranexamic acid is commonly used in joint replacement surgery.
Tranexamic acid should be considered for use in bleeding trauma patients.
Tranexamic acid, also known as tranexamic acid, with the chemical name trans-4-aminomethylcyclohexanecarboxylic acid, white crystalline powder; odorless, slightly bitter taste. Soluble in water, almost insoluble in ethanol, acetone, chloroform or ether. The molecular formula is C8H15NO2, the molecular weight is 157.21000, the density is 1.095 g/cm3, the melting point is 233ºC, and the boiling point is 300.2ºC at 760 mmHg. The phenomenon of fibrinolysis is related to the breakdown of fibrin in the body under physiological or pathological conditions, the increase in vascular permeability, etc., and to the development and cure of body reactions, various bleeding symptoms and allergies caused by fibrinolysis. Tranexamic acid can inhibit the action of this plasmin, while showing hemostatic, anti-allergic, and anti-inflammatory effects.